Healthcare [ 11/13 ] | Biotechnology [ 91/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 7, 24 | 0 Increased by +100% | -0.09 Increased by +100% |
| Mar 8, 24 | 0 Increased by +100% | -0.09 Increased by +100% |
| Jan 16, 24 | -0.09 Increased by +25% | -0.09 |
| Sep 6, 23 | -0.08 Increased by +11.11% | -0.09 Increased by +11.11% |
| Jun 14, 23 | -0.07 Increased by +41.67% | -0.11 Increased by +36.36% |
| Mar 17, 23 | -0.08 Increased by +38.46% | -0.16 Increased by +50% |
| Jan 4, 23 | -0.12 Increased by +7.69% | -0.11 Decreased by -9.09% |
| Sep 9, 22 | -0.09 Increased by +35.71% | -0.13 Increased by +30.77% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Oct 31, 23 | 0 Decreased by -100% | -2.69 M Increased by +20.79% | Decreased by N/A% Decreased by N/A% |
| Jul 31, 23 | 0 Decreased by N/A% | -2.51 M Increased by +7.07% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 23 | 210 K Increased by +N/A% | -2.04 M Increased by +42.55% | Decreased by -969.05% Decreased by N/A% |
| Jan 31, 23 | 0 Decreased by N/A% | -2.12 M Increased by +44.63% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 22 | 2.47 B Increased by +68.23 K% | -3.4 M Increased by +15.38% | Decreased by -0.14% Increased by +99.88% |
| Jul 31, 22 | 0 Decreased by N/A% | -2.7 M Increased by +37.66% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 22 | 0 Decreased by N/A% | -3.54 M Decreased by -47.65% | Decreased by N/A% Decreased by N/A% |
| Jan 31, 22 | 0 Decreased by -100% | -3.83 M Decreased by -73.39% | Decreased by N/A% Decreased by N/A% |
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.